These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Discovery of Entamoeba histolytica hexokinase 1 inhibitors through homology modeling and virtual screening.
    Author: Saucedo-Mendiola ML, Salas-Pacheco JM, Nájera H, Rojo-Domínguez A, Yépez-Mulia L, Avitia-Domínguez C, Téllez-Valencia A.
    Journal: J Enzyme Inhib Med Chem; 2014 Jun; 29(3):325-32. PubMed ID: 23534932.
    Abstract:
    Entamoeba histolytica, the parasite which causes amebiasis is responsible for 110,000 deaths a year. Entamoeba histolytica depends on glycolysis to obtain ATP for cellular work. According to metabolic flux studies, hexokinase exerts the highest flux control of this metabolic pathway; therefore, it is an excellent target in the search of new antiamebic drugs. To this end, a tridimensional model of E. histolytica hexokinase 1 (EhHK1) was constructed and validated by homology modeling. After virtual screening of 14,400 small molecules, the 100 with the best docking scores were selected, purchased and assessed in their inhibitory capacity. The results showed that three molecules (compounds 2921, 11275 and 2755) inhibited EhHK1 with an I50 of 48, 91 and 96 µM, respectively. Thus, we found the first inhibitors of EhHK1 that can be used in the search of new chemotherapeutic agents against amebiasis.
    [Abstract] [Full Text] [Related] [New Search]